Phosphodiesterase type 5 inhibitors’ extended duration of response as a variable in the treatment of erectile dysfunction
Authors:
Open Access
- 1 June 2006
- journal article
- review article
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 19 (2) , 119-123
Abstract
The phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, tadalafil and vardenafil, are a class of medications that are safe and effective in treating erectile dysfunction (ED). Yet, resuming sexual activity following a period of abstinence in response to ED may be anxiety-provoking for the man, his partner and their relationship, causing the sexual encounter to become a stressful event. The differences between PDE5 inhibitors in terms of duration of action can be successfully utilized by healthcare professionals to mitigate some of the psychosocial barriers that interfere with treating ED. PDE5 inhibitors with a longer duration of responsiveness provide some men with ED and their partners, a treatment option that may offer greater flexibility and potentially less anxiety surrounding the resumption of sexual activity. Shorter-acting PDE5s may be preferred by men/couples with predictable sexual scripts, excellent communication strategies and concerns regarding the duration of side effects.Keywords
This publication has 31 references indexed in Scilit:
- Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring the Therapeutic WindowEuropean Urology, 2004
- The Psychological and Interpersonal Relationship Scales: Assessing Psychological and Relationship Outcomes Associated with Erectile Dysfunction and Its TreatmentArchives of Sexual Behavior, 2004
- Psychotherapy for Erectile Dysfunction: Now More Relevant Than EverEndocrine, 2004
- Sex coaching for physicians: combination treatment for patient and partnerInternational Journal Of Impotence Research, 2003
- Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trialUrology, 2003
- Longitudinal Differences in Disease Specific Quality of Life in Men With Erectile Dysfunction: Results From the Exploratory Comprehensive Evaluation of Erectile Dysfunction StudyJournal of Urology, 2003
- Quality of life and erectile dysfunctionUrology, 2002
- Onset and duration of action of sildenafil for the treatment of erectile dysfunctionBritish Journal of Clinical Pharmacology, 2002
- When an erection alone is not enough: biopsychosocial obstacles to lovemakingInternational Journal Of Impotence Research, 2002
- The role of the partner in erectile dysfunction and its treatmentInternational Journal Of Impotence Research, 2002